000282369 001__ 282369
000282369 005__ 20240304140229.0
000282369 0247_ $$2doi$$a10.1007/s00066-023-02129-y
000282369 0247_ $$2pmid$$apmid:37640867
000282369 0247_ $$2ISSN$$a0179-7158
000282369 0247_ $$2ISSN$$a1439-099X
000282369 037__ $$aDKFZ-2023-01751
000282369 041__ $$aEnglish
000282369 082__ $$a610
000282369 1001_ $$00000-0001-8222-2288$$aFink, C. A.$$b0
000282369 245__ $$aWhole-pelvic irradiation with boost to involved nodes and prostate in node-positive prostate cancer-long-term data from the prospective PLATIN-2 trial.
000282369 260__ $$aHeidelberg$$bSpringer Medizin$$c2024
000282369 3367_ $$2DRIVER$$aarticle
000282369 3367_ $$2DataCite$$aOutput Types/Journal article
000282369 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1709557309_15773
000282369 3367_ $$2BibTeX$$aARTICLE
000282369 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282369 3367_ $$00$$2EndNote$$aJournal Article
000282369 500__ $$a2024 Mar;200(3):202-207
000282369 520__ $$aNode-positive prostate cancer is a potentially curable disease. Definitive radiotherapy to the prostate and lymphatic drainage is an effective treatment option but prospective long-term outcome data are scarce. Thus, the current study aimed to evaluate the toxicity and efficacy of definitive radiation therapy for men with prostate cancer and nodal metastases using modern irradiation techniques.A total of 40 treatment-naïve men with node-positive prostate cancer were allocated to the trial. All patients received definitive radiation therapy at two German university hospitals between 2009 and 2018. Radiation was delivered as intensity-modulated radiation therapy (IMRT) with 51 Gy to the lymphatic drainage with simultaneous integrated boost (SIB) up to 61.2 Gy to involved nodes and 76.5 Gy to the prostate in 34 fractions. Feasibility and safety, overall and progression-free survival, toxicity, and quality of life measurements were analyzed.During a median follow-up of 79 months, median overall survival was 107 months and progression-free survival was 78 months. Based on imaging follow-up, no infield relapse was reported during the first 24 months of follow-up. There were 3 (8%) potentially treatment-related grade 3 toxicities. Common iliac node involvement was associated with a higher risk of progression (HR 15.8; 95% CI 2.1-119.8; p = 0.007).Definitive radiation to the lymphatic drainage with SIB to the involved nodes and prostate is a safe and effective treatment approach for patients with treatment-naïve, node-positive prostate cancer with excellent infield tumor control rates and tolerable toxicity. Location rather than number of involved nodes is a major risk factor for progression.
000282369 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000282369 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000282369 650_7 $$2Other$$aPelvic lymph node
000282369 650_7 $$2Other$$aQuality of life
000282369 650_7 $$2Other$$aRadiotherapy
000282369 650_7 $$2Other$$aRegional and distant metastasis
000282369 650_7 $$2Other$$aToxicity
000282369 7001_ $$aWegener, D.$$b1
000282369 7001_ $$aSauer, L. D.$$b2
000282369 7001_ $$aJäkel, C.$$b3
000282369 7001_ $$aZips, D.$$b4
000282369 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, J.$$b5$$udkfz
000282369 7001_ $$0P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc$$aHerfarth, Klaus$$b6
000282369 7001_ $$aKoerber, S. A.$$b7
000282369 773__ $$0PERI:(DE-600)2003907-4$$a10.1007/s00066-023-02129-y$$n3$$p202-207$$tStrahlentherapie und Onkologie$$v200$$x0179-7158$$y2024
000282369 909CO $$ooai:inrepo02.dkfz.de:282369$$pVDB
000282369 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000282369 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000282369 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000282369 9141_ $$y2023
000282369 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-11$$wger
000282369 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-11$$wger
000282369 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-11
000282369 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-11
000282369 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-11
000282369 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-28
000282369 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-28
000282369 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-28
000282369 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-28
000282369 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-28
000282369 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-28
000282369 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTRAHLENTHER ONKOL : 2022$$d2023-08-28
000282369 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-28
000282369 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000282369 980__ $$ajournal
000282369 980__ $$aVDB
000282369 980__ $$aI:(DE-He78)E050-20160331
000282369 980__ $$aUNRESTRICTED